2. Academic Validation
  3. Design and Synthesis of Pyrazolomorphinan Derivatives as Novel Delta Opioid Receptor Agonists

Design and Synthesis of Pyrazolomorphinan Derivatives as Novel Delta Opioid Receptor Agonists

  • J Med Chem. 2025 Dec 25;68(24):25794-25808. doi: 10.1021/acs.jmedchem.5c02499.
Hideaki Fujii 1 2,  Chiharu Iwamatsu 1,  Saki Ishizaki 1,  Hideki Nakamura 3,  Daisuke Yamada 4,  Shuma Yamada 1,  Junichi Niwa 1,  Toshinori Yoshioka 4,  Pengfei Liu 4,  Shintaro Shirakura 4,  Fumika Karaki 1 2,  Shigeto Hirayama 1 2,  Akiyoshi Saitoh 4
Affiliations

Affiliations

  • 1 Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University, 5-9-1, Shirokane, Minato-ku, Tokyo 108-8641, Japan.
  • 2 Medicinal Research Laboratories, School of Pharmacy, Kitasato University, 5-9-1, Shirokane, Minato-ku, Tokyo 108-8641, Japan.
  • 3 Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., 1-22, Hikokawado, Misato, Saitama 341-0005, Japan.
  • 4 Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba 278-8510, Japan.
PMID: 41335044 DOI: 10.1021/acs.jmedchem.5c02499
Abstract

We designed pyrazolomorphinan derivatives 3 as novel δ Opioid Receptor (DOR) selective agonists with an unprecedented chemotype according to the drug design concept for the DOR selective agonist KNT-127 which encompassed the message-address concept, the accessory site concept, and the conversion of an indole ring into a quinoline ring. The designed compounds 3 as well as their regioisomers 9 showed potent DOR agonistic activities with low or almost no activities for the μ (MOR) and κ opioid receptors (KOR). Among the tested compounds, SYK-1106 (9j) bearing a cyclohexyl substituent was the most potent and efficacious DOR agonist (DOR: EC50 = 0.089 nM, Emax = 111%; agonistic activities for the MOR and KOR were not determined). SYK-1106 showed dose-dependent and DOR antagonist NTI reversible antidepressant-like effects at 0.3 mg/kg, s.c. in the mouse forced-swimming tests without an effect on locomotor activity and with no convulsive effects.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z